Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer

But Has Ground To Make Up On Tecentriq

Executive Summary

An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.

You may also be interested in...



Keytruda TNBC Approval Now More Likely, But Data Is Bad News For pCR Surrogate Endpoint

Merck unveiled event-free survival results for Keytruda in triple-negative breast cancer following failure earlier this year to gain approval on a surrogate endpoint.

Keytruda To Enjoy First-To-Market Advantage As TNBC Approval Now More Likely

Merck & Co. unveiled event-free survival data for Keytruda in triple-negative breast cancer, following a failure earlier this year to gain approval on a surrogate endpoint.

Merck & Co.’s Keytruda Gets Fighting Chance In TNBC

The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel